Showing 91-100 of 325 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Sequential multi-molecule release from nanofiber scaffolds for improved stem cell-derived islet transplantation under the skin | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2026 | $845.444,86 |
| Targeted delivery of therapeutics to islet beta cells for preventing and treating diabetes | UT Southwestern | Juanzhu Yan | Cures | 01-March-2025 to 29-February-2028 | $285.000,00 |
| Employing PD-L1-Modified Biomaterials to Induce Islet Allograft Tolerance Following Perihepatic Transplantation in Nonhuman Primates | Regents of the University of Minnesota | Melanie Graham | Cures | 01-April-2025 to 31-March-2027 | $918.744,88 |
| Development of β-Cell Targeted Lipid Nanoparticle Therapeutics | The University of Chicago | Jacob Ryan Enriquez | Cures | 01-March-2025 to 29-February-2028 | $247.790,00 |
| Engineering hypoimmune cells for Type 1 Diabetes | New York Stem Cell Foundation, Inc. | Daniel Paull | Cures | 01-May-2025 to 30-April-2028 | $1.498.415,83 |
| Achieving persistent presentation of self-antigens to reestablish tolerance and prevent autoimmune diabetes | Trustees of Columbia University in the City of New York | Camillo Bechi Genzano | Cures | 01-March-2025 to 29-February-2028 | $256.285,00 |
| Mesh Oxygen Transporter for improved engraftment of human stem cell-derived pancreatic islet cells in the subcutaneous site | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 30-June-2026 | $294.796,07 |
| A novel approach to overcome innate immunity in beta-cell replacement therapy for type 1 diabetes | Baylor Research Institute | Bashoo Naziruddin | Cures | 01-January-2025 to 31-December-2027 | $749.769,68 |
| Spatial and temporal regulation of proangiogenic factors to support islet cell transplantation | William Marsh Rice University | Omid Veiseh | Cures | 01-January-2025 to 31-December-2027 | $900.000,00 |
| A Novel Bifunctional Biologic for Type 1 Diabetes | Johns Hopkins University | Giorgio Raimondi | Cures | 01-February-2025 to 31-January-2028 | $995.376,00 |